Why Wegovy's High Cost Deters Many Patients
Wegovy, Novo Nordisk's semaglutide injection for weight loss, lists at around $1,350 per month without insurance in the US, making it unaffordable for most out-of-pocket payers.[1] Patients often cite this as the top barrier, with surveys showing 40-60% abandoning treatment due to cost, even when motivated by obesity-related health risks.[2]
Does Insurance Coverage Make It Accessible?
Coverage varies: Medicare Part D excludes weight-loss drugs like Wegovy, forcing many seniors to pay full price or skip it.[3] Commercial plans cover it for some (e.g., 50-70% of large employers), but with high copays ($100-500/month) or prior authorizations requiring BMI proof and failed diets.[4] Uninsured patients face the full $16,200 yearly cost, leading 70% to forgo starting, per real-world claims data.[2]
How Patients Weigh Cost Against Weight Loss Benefits
Those who start often see 15-20% body weight loss in trials, improving diabetes risk and mobility, but many quit after 6-12 months when savings run out—dropout rates hit 50% in cost-exposed groups.[5] Patient forums report trading Wegovy for cheaper alternatives when bills exceed $1,000/month, prioritizing rent or groceries over sustained use.
What Cheaper Alternatives Do Patients Switch To?
- Compounded semaglutide: $200-500/month from telehealth like Hims or Ro, but FDA warns of contamination risks after shortages ended.[6]
- Oral versions like Rybelsus: $900-1,000/month, same active ingredient but lower adherence due to daily pills.[1]
- Older drugs like phentermine: $20-50/month, less effective (5-10% loss) but widely covered.[7]
Patients switching save 60-90% but report 30-50% less weight loss efficacy.[5]
When Does Wegovy Get Cheaper?
Patent protection lasts until 2030-2032 (US composition patent expires 2030; others extend via litigation).[8] Biosimilars could drop prices 30-80% post-patent, as seen with Humira. Novo Nordisk's savings cards cap costs at $225/month for eligible insured patients (income under $100K), used by 40% of starters.[9] Generic entry might not arrive until 2032 amid ongoing lawsuits.
Real Patient Stories on Cost Tradeoffs
Reddit and GoodRx reviews highlight dilemmas: a 35-year-old lost 50 lbs on Wegovy but stopped at $1,200/month, regaining 20 lbs on metformin ($10/month).[10] Another with employer coverage stuck with it for heart benefits, despite $300 copays straining family budgets. Cost drives 25% to buy from Canada ($800/month) or split doses, risking underdosing.[11]
[1]: GoodRx - Wegovy Prices
[2]: JAMA Network - Semaglutide Discontinuation
[3]: CMS - Medicare Coverage for GLP-1s
[4]: IQVIA - Employer Coverage Report
[5]: NEJM - STEP Trials Long-Term Data
[6]: FDA - Compounded Semaglutide Alert
[7]: GoodRx - Phentermine Prices
[8]: DrugPatentWatch - Wegovy Patents
[9]: Novo Nordisk - Wegovy Savings Card
[10]: Reddit r/Wegovy - Cost Discussions
[11]: KFF - GLP-1 Access Survey